(Q47981726)

7 February 2018

review article

1 reference

title

Should-alpha-interferon be included as standard treatment in multiple myeloma? (English)

1 reference

7 February 2018

author name string

Ludwig H

1

1 reference

7 February 2018

Fritz E

2

1 reference

7 February 2018

Zulian GB

3

1 reference

7 February 2018

Browman GP

4

1 reference

7 February 2018

publication date

1 January 1998

1 reference

7 February 2018

European Journal of Cancer

published in

1 reference

7 February 2018

volume

34

1 reference

7 February 2018

issue

1

1 reference

7 February 2018

page(s)

12-24

1 reference

7 February 2018

Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Interferon and natural killer activity in multiple myeloma. Lack of correlation between interferon-induced enhancement of natural killer activity and clinical response to human interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Natural killer cell activity in monoclonal gammopathies: Relation to disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Augmentation of human monocyte-mediated cytolysis by interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Interferon therapy for neoplastic diseases in man in vitro and in vivo studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Recombinant interferon- γ inhibits the growth of IL-6-dependent human multiple myeloma cell lines in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Development of transformed phenotype induced by a human ras oncogene is inhibited by interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Interferon therapy in myelomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Leukocyte Interferon-Induced Tumor Regression in Human Metastatic Breast Cancer, Multiple Myeloma, and Malignant Lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Treatment of multiple myeloma with recombinant interferon alfa-2a

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Interferon in the Treatment of Refractory Multiple Myeloma: An Eastern Cooperative Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Combined recombinant human interferon alpha 2 and cytotoxic agents studied in a clonogenic assay

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Randomized clinical trials in oncology. Principles and obstacles.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Reappraisal of plateau phase in myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Role of G0-G1 arrest in the inhibition of tumor cell growth by interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Noncycling Tumor Cells Are Sensitive Targets for the Antiproliferative Activity of Human Interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Alternating combination chemotherapy and interferon improves survival in poor prognosis multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Alpha-2a-interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

A randomised trial of cyclophosphamide with and without low dose alpha-interferon in the treatment of newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Alpha-interferon combination therapy of resistant myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAM Dex) induction chemotherapy and interferon maintenance treatment in multiple myeloma. Current results of a multicenter trial. The German Myeloma Tr

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Double hemibody irradiation (DHBI) in the management of relapsed and primary chemoresistant multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Interferons in the treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

The Current Position of Allogeneic and Autologous BMT in Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Myeloma during a decade: clinical experience in a single centre

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Autologous stem cell transplantation in multiple myeloma: results of the European Group for Bone Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Recombinant interferon-alpha combined with prednisone in metastatic renal cell carcinoma. Reduced toxicity without reduction of the response rate--a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Combination of interferon and dexamethasone in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Multiple myeloma: intensified maintenance therapy with recombinant interferon-alpha-2b plus glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Obtaining data from randomised controlled trials: how much do we need for reliable and informative meta-analyses?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2910046-6

7 January 2021

10.1016/S0959-8049(97)10046-6

Identifiers

DOI

1 reference

7 February 2018

1 reference

7 February 2018